Table 2 Characteristics of the healthy population used for lisinopril PBPK model development
Population Ethnicity | Population Size (n) | Proportion of female | Age (years) | Dose (mg) | Application | References |
|---|---|---|---|---|---|---|
European | 12 | 0 | 21–34 | 2.97 | Single IV bolus | [41] |
5.53 | ||||||
11.20 | ||||||
Caucasians | 18 | 0 | 21–37 | 20 | Single oral dose | [42] |
European | 28 | 0 | 18–42 | 20 | Single oral dose | [26] |
European | 8 | 0 | 22–31 | 20 | Single oral dose for 10 days | [41] |
Neonates to Infants | 100 | 50 | 0.25–1.0 | 5 | Single oral dose | Current study |
2.5 | ||||||
1.5 | ||||||
Neonates to toddler | 100 | 50 | 0.25–1.9 | 20 | Single oral dose | |
10 | ||||||
5 | ||||||
2.5 | ||||||
1.5 | ||||||
Pre-schools children | 100 | 50 | 2–5 | 20 | Single oral dose | |
10 | ||||||
5 | ||||||
2.5 | ||||||
1.5 | ||||||
School children | 100 | 50 | 5–12 | 20 | Single oral dose | |
10 | ||||||
5 | ||||||
2.5 | ||||||
1.5 | ||||||
Adolescent | 100 | 50 | 12–16 | 20 | Single oral dose | |
10 |